Soleno Therapeutics/$SLNO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Soleno Therapeutics
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.
Ticker
$SLNO
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
115
ISIN
US8342033094
Website
SLNO Metrics
BasicAdvanced
$3.7B
-
-$4.65
-2.67
-
Price and volume
Market cap
$3.7B
Beta
-2.67
52-week high
$80.99
52-week low
$36.93
Average daily volume
955K
Financial strength
Current ratio
19.637
Quick ratio
18.432
Long term debt to equity
22.473
Total debt to equity
22.73
Interest coverage (TTM)
-128.22%
Management effectiveness
Return on assets (TTM)
-52.40%
Return on equity (TTM)
-105.54%
Valuation
Price to book
15.31
Price to tangible book (TTM)
15.74
Price to free cash flow (TTM)
-34.933
Growth
Earnings per share change (TTM)
106.82%
3-year earnings per share growth (CAGR)
-3.69%
SLNO News
AllArticlesVideos
Soleno Therapeutics Announces Submission and EMA Validation of Marketing Authorization Application for Diazoxide Choline Prolonged-Release Tablets for the Treatment of Hyperphagia in Patients with Prader-Willi Syndrome
GlobeNewsWire·14 hours ago
Soleno Therapeutics Announces Data Presentation Showing that Resumption of Treatment with VYKAT(TM) XR after a Randomized Withdrawal Period was Associated with Significant Improvements in Hyperphagia and Behavioral Symptoms in Participants with Prader-Willi Syndrome
GlobeNewsWire·3 days ago
Soleno Therapeutics, Inc. (SLNO) Q1 2025 Earnings Call Transcript
Seeking Alpha·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Soleno Therapeutics stock?
Soleno Therapeutics (SLNO) has a market cap of $3.7B as of May 23, 2025.
What is the P/E ratio for Soleno Therapeutics stock?
The price to earnings (P/E) ratio for Soleno Therapeutics (SLNO) stock is 0 as of May 23, 2025.
Does Soleno Therapeutics stock pay dividends?
No, Soleno Therapeutics (SLNO) stock does not pay dividends to its shareholders as of May 23, 2025.
When is the next Soleno Therapeutics dividend payment date?
Soleno Therapeutics (SLNO) stock does not pay dividends to its shareholders.
What is the beta indicator for Soleno Therapeutics?
Soleno Therapeutics (SLNO) has a beta rating of -2.67. This means that it has an inverse relation to market volatility.